CDC42BPA and prostate carcinoma: Our findings show that the bioactivity of this isolate not only inhibits MRCKα known to be associated with prostate cancer, but also reduced the viability of two prostate cancer cell lines, PC-3 and DU145 implicating the validity of these results in anti-cancer drug discovery.